BlockMedx, is a blockchain company in Pharma tech that is joining WanLabs and operating on Wanchain. They are a healthcare infrastructure project focusing on prescription drug fraud, abuse, and non-adherence. BlockMedx is building a next-generation smart e-prescribing and analytics ecosystem that can be used anywhere in the world to send and receive electronic prescriptions, predict patient risk behaviors, and automate micropayment incentives using the token economy to incentivize healthy behavior.

Starts 2 weeks, 2 days from now

Token Sale 10/08/2018 midnight - Unspecified
Country Netherlands
Member of this ICO only
A
Alexander Antoniou
FOUNDER & CHIEF MEDICAL OFFICER
Member of this ICO only
J
Justin Liao
HEAD OF GLOBAL BUSINESS
Member of this ICO only
M
Matthew Mitchell
SENIOR BLOCKCHAIN ENGINEER
Participates in 2 ICOs
D
Danny Holland
FULL-STACK & BLOCKCHAIN DEVELOPER
Participates in 2 ICOs
L
Leila Kassiri
SOFTWARE ENGINEER
Member of this ICO only
M
Mario Hoyos
FULL STACK DEVELOPER
Member of this ICO only
B
Brynne Kelsey
DIRECTOR OF GOVERNMENT RELATIONS
Member of this ICO only
P
Patrick Hull
DIRECTOR OF PARTNERSHIPS
Member of this ICO only
Advisors
L
Luke Szkudlarek
SWISS AMBASSADOR, MARKETING & GROWTH ADVISOR
Participates in 7 ICOs
D
Dave Hoover
BLOCKCHAIN EXPERT & ENGINEER
Participates in 3 ICOs
J
Jim Kyung-Soo Liew
SENIOR ADVISOR, ML/AI EXPERT
Participates in 2 ICOs
A
Alexei Strasser
SWISS AMBASSADOR, TOKENOMICS & FUNDRAISING EXPERT
Participates in 2 ICOs

Starts 2 weeks, 2 days from now

Token Sale 10/08/2018 midnight - Unspecified
Country Netherlands

Financial information

Platform Wanchain
Whitelist/KYC Whitelist & KYC
Bonus Available

Interest

Alexa rank 3,806,973 th
Telegram participants 2,343
Twitter followers 435
Promotional video views 102
Similar icos
Disclaimer

TrackICO does not encourage investing in any ICOs published on the platform. Make sure to do your own thorough research before putting money into Initial Coin Offerings. All content on TrackICO is meant to be used for information purposes only, and should not be taken as financial or investment advice.